Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. - Wikidata - awgldk - TriplyDB

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

http://www.wikidata.org/entity/Q33364092

about

Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome Atypical hemolytic uremic syndrome Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome Hemolytic uremic syndrome: new developments in pathogenesis and treatment Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome The molecular biology of thrombotic microangiopathy Current concepts in thrombotic thrombocytopenic purpura Pathogenesis of thrombotic microangiopathies Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy Hemolytic uremic syndrome Current Understanding of the Role of Complement in IgA Nephropathy Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature Complement System Part II: Role in Immunity Production of biologically active complement factor H in therapeutically useful quantities Haemolytic uraemic syndrome.Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia.Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?Thrombotic microangiopathy after kidney transplantation.Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population.Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure.Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.Thrombotic microangiopathies: multimers, metalloprotease, and beyond.Atypical hemolytic uremic syndrome in the Tunisian population.Genetics and complement in atypical HUS.aHUS caused by complement dysregulation: new therapies on the horizon.A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome.Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.

P2860

Q21145235-3C0E2120-B8F0-41FB-8035-4D892FC87B7F Q21202864-C70E33EB-BDB0-4C95-BFD6-911BCE8A18B1 Q24601710-C07F6268-2C5C-4F11-B056-D9E755A7A855 Q24606843-19EABBF7-942A-42E8-9122-FF09096B9B9A Q24613517-2C63AE6F-B2A7-4419-BDF9-F549C68ABC33 Q24613907-A64ADDDD-2951-4E0A-9ABE-29B8D2D5397A Q24634697-B926E476-2B81-4BDB-91D0-DA14A707996F Q24648686-E9B3A586-5F03-4158-9A65-8B3C18E3492A Q24656680-03030436-D1B5-418C-AF98-C8D2A8B01B30 Q24658043-6B58D5C8-2065-4468-81D1-4CFE4DE89391 Q24685473-7AB498E1-E2D9-4BDC-AD05-5740852CDB42 Q26739894-6B80D588-8040-457A-B627-E02E4309DAF1 Q26747416-B3906201-B0BA-4E09-817A-42DAFC942461 Q26799054-6F8AF187-1A15-4B4A-8F2B-833BA3745F97 Q26852163-9F9C6396-5D1E-4F1F-BAAF-A6E8FCDC5161 Q26864297-C7315EC3-C6FC-4C9E-A27D-13F95A4CA076 Q28263460-9558AFE4-0D91-437C-BF49-5C047107AB43 Q28300280-0311D3F0-A76F-467C-8CA1-170B4CF85653 Q30244707-6BAE6B0F-4E29-4672-BE44-D3EAAF3F7B9D Q33370397-864073BA-9C24-42B1-A499-0DD74A06D680 Q33372160-BB74EC32-CAED-429D-BC72-24060E28E464 Q33372382-9B847132-6456-4F3D-9BB7-1CD2D968CCB9 Q33372586-54034560-DB33-4755-B0A0-060708FEAE00 Q33372850-D9BE0DEE-CEAC-40AB-9F07-015A56136E89 Q33372897-1A464C4E-4BAC-43A7-8CA2-1478A95364E6 Q33375866-D8B071E0-53A8-4F22-9A57-F2674355D793 Q33377727-15B9A408-EB97-4B91-91B4-4B52EEC98640 Q33377799-8FD30A15-4E43-4D42-95AE-08E4A8B829FE Q33378469-3B99AE65-126B-4DE7-AE32-2D979F72C5AB Q33382404-45389B7C-7F05-474D-953A-4B6F311C89CA Q33385035-E0A882A6-DA25-40D5-A4D8-131B90B934B2 Q33385154-07C5565F-2915-4C7A-8A17-3F418EF4DDE9 Q33385329-BC4B6A93-A6B7-43F0-AF47-7444E94E33DE Q33387252-8ED1D127-9A2A-4281-9203-76BD8293979B Q33389435-FA4452A1-4E08-4300-9FB0-F72E81F28884 Q33389773-16C5CBB1-A0FA-41B0-B7DE-220D9EE92AA6 Q33389945-01564EEB-C717-4A11-90B7-FF3A5B776E36 Q33390198-147EDF93-61AF-4468-B3A0-91FF6535A6DE Q33392449-ACA27B23-FD50-4611-86BA-11F051A4BF89 Q33393852-718489F3-7637-4627-8FD4-EBBA2FA6F92D

P2860

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

http://www.wikidata.org/entity/Q33364092

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@ast

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@en

type

label

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@ast

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@en

prefLabel

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@ast

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@en

P1433

Q33364092-8EDA65B8-1B40-4F5D-B8F2-9762CA23E663

P1476

Q33364092-F20D6A09-5274-4F4D-91D0-423DD690C54B

P2093

Q33364092-0FAC65B1-3AE5-4023-B39A-6BF0C23B5920

Q33364092-5A346573-43EE-455F-A54C-015D594D394F

Q33364092-70D06655-FDC5-4AF0-8297-AC5CBB57F1ED

Q33364092-78B5B066-B56B-4BC6-9B5F-2FE673BCE392

Q33364092-7932A059-7EC0-4273-B26B-C02002FE2C6E

Q33364092-C216B5CA-EE53-4EC6-9A66-8BE648BDD465

Q33364092-CE186DDF-D4AA-4786-9FA6-FB78DE6E550C

P304

Q33364092-1484722E-C814-4535-849E-9EC7AF7445FA

P31

Q33364092-53263AD0-A2F8-47C0-BD38-8B28FE81AC96

P356

Q33364092-5F1BD91C-4A6F-444A-8048-E307979307C1

P433

Q33364092-611B2539-91B9-482F-8032-E7D70C17623D

P478

Q33364092-38EF0C80-00C6-41D8-BFF2-60178A2AFB5B

P50

Q33364092-1124C7BE-7926-46DA-938F-C7056E094080

Q33364092-24E22A70-2391-4478-917F-E51E4B0621F4

Q33364092-881C3B5F-DD1C-4D13-93A4-559836482D5B

Q33364092-BB28CC77-3895-499A-BE02-A4CE0FA170BD

P577

Q33364092-EED8E254-8C5E-46F8-8A8A-96C01A46052A

P698

Q33364092-3AE551F4-5412-464C-BBCF-46ED9874FA7B

P921

Q33364092-2A68E60C-8364-45FD-9E4E-48C1E3A6D273

P356

P1433

Journal of the American Society of Nephrology

P1476

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

@en

P2093

Chantal Loirat

http://www.w3.org/2001/XMLSchema#string

Hubert Nivet

http://www.w3.org/2001/XMLSchema#string

Jacques Blouin

http://www.w3.org/2001/XMLSchema#string

Laurence Weiss

http://www.w3.org/2001/XMLSchema#string

Marie-Alice Macher

http://www.w3.org/2001/XMLSchema#string

Sylvie Cloarec

http://www.w3.org/2001/XMLSchema#string

Véronique Frémeaux-Bacchi

http://www.w3.org/2001/XMLSchema#string

P304

555-563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2004050380

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Véronique Frémeaux-Bacchi

Wolf Hervé Fridman

Marie-Alice Macher

Marie-Agnès Dragon-Durey

P577

2004-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15590760

http://www.w3.org/2001/XMLSchema#string

P921